Table 2.

Activity of selinexor in combination with established myeloma therapies in cell lines.

Cell line(s)	Drug(s) added	Model	Effect	Reference
MM1.S	Dexamethasone	in vitro, in vivo	Synergistic	Argueta et al.1
MM1.S	Dexamethasone	in vitro	Additive/Synergistic	Chen et al.2
MM1.S	Dexamethasone	in vivo	Synergistic	Chen et al.3
MM1.S	Dexamethasone	in vitro	Synergistic	Landesman et al.4
MM1.S	Lenalidomide	in vivo	Synergistic	Carlson et al.5
MM1.S	Bortezomib	in vivo	Additive	Muz etal.6
H929, RPMI-8226, U266B1	Bortezomib, Carfilzomib	in vitro	Synergistic	Turner et al.7
U266, RPMI-8226	Bortezomib, Carfilzomib	in vitro, in vivo	Synergistic	Turner et al.8
Primary bone marrow mononuclear cells	Carfilzomib	in vitro	Synergistic	Rosebeck et al.9
H929, RPMI-8226	Doxorubicin, Bortezomib, Carfilzomib	in vitro, ex vivo	Synergistic	Turner et al.10
U266, RPMI-8226, Patient MM cells	Ixazomib	in vitro, in vivo	Additive/Synergistic	Turner et al.11
MM1.S, H929	Panobinostat	in vitro	Synergistic	Elloul et al.12
RPMI-8226, U266, H929, patient MM cells	Melphalan	in vitro, ex vivo	Synergistic	Cui et al.13
H929, RPMI-8226, U266	Melphalan	in vitro, ex vivo	Synergistic	Turner et al.14
H929, RPMI-8226, U266	Liposomal Doxorubicin	in vitro, in vivo	Synergistic	Turner et al.15

¹Argueta C, Kashyap T, Klebanov B, et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget 2018; 9: 25529–25544.

²Chen C, Gutierrez M, Brown P, et al. Anti-tumor activity of selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE), +/– dexamethasone in multiple myeloma preclinical models & translation in patents with multiple myeloma. Presented at the European Hematology Association 2014 Annual Meeting, Lombardy, Italy. Abstract P953.

³Chen C, Gutierrez M, Siegel DS, et al. Selinexor demonstrates marked synergy with dexamethasone (Sel-Dex) in preclinical models and in patients with heavily pretreated refractory multiple myeloma (MM). Blood 2014; 124: 4773.

⁴Landesman Y, Kashyap T, Klebanov B, et al. Selective inhibitor of nuclear export (SINE) compounds show synergistic anti-tumor activity in combination with dexamethasone in multiple myeloma. Presented at the AACR 2015 Annual Meeting, Philadelphia, PA. Abstract 2074.

⁵Carlson R, et al. In Vitro and in vivo anti-multiple myeloma activity of selinexor (KPT-330), an oral selective inhibitor of nuclear export (Sine™) compound, is enhanced through combination with standard anti–myeloma agents. Presented at the European School of Hematology: 2nd International Conference on Multiple Myeloma, 7–9 November 2014, Athens, Greece. Abstract 2461.

⁶Muz B, Azab F, de la Puente P, et al. Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma. Transl Oncol 2017; 10: 632–640.

⁷Turner JG, Dawson JL, Cubitt CL, et al. Combination therapy of human multiple myeloma using proteosome and CRM1 inhibitors. Presented at the AACR 2013 Annual Meeting, Washington, DC. Abstract 2066.

⁸Turner JG, Kashyap T, Dawson JL, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget 2016; 7: 78896–78909.

⁹Rosebeck S, Alonge MM, Kandarpa M, et al. Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor. Mol Cancer Ther 2016; 15: 60–71.

¹⁰Turner JG, Dawson J, Emmons MF, et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer 2013; 4: 614–625.

¹¹Turner JG, Dawson J, Bauer A, et al. Ixazomib combined with the nuclear export inhibitors selinexor or eltanexor for the treatment of multiple myeloma. Presented at the AACR 2019 Annual Meeting, Atlanta, GA. Abstracts 285.

¹²Elloul S, Chang H, Klebanov B, et al. Synergistic antitumor effect of selinexor, a selective inhibitor of nuclear export (SINE) compound and panobinostat in a mouse model of multiple myeloma. Presented at the AACR 2016 Annual Meeting, New Orleans, LA. Abstract 4720.

¹³Cui Y, Turner JG, Dawson JL, et al. The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma. Blood 2016; 128: 5662

¹⁴Turner JG, Dawson JL, Grant S, et al. Melphalan and XPO1 inhibitor combination therapy for the treatment of multiple myeloma. Blood 2014; 124: 2084.

¹⁵Turner JG, Dawson JL, Grant S, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 2016; 9: 73.